Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Relapsing polychondritis (RP) is a rare disease of unknown etiology characterized by recurrent episodes of inflammation resulting in the destruction of cartilaginous tissues. We describe a young girl with RP unresponsive to conventional therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00296-009-0981-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Case of Relapsing Polychondritis with Multisystemic Involvement.
Clin Cosmet Investig Dermatol
August 2025
Department of Imaging, The Fifth People's Hospital of Hainan Province, Haikou, Hainan, People's Republic of China.
Relapsing polychondritis is a rare immunologic disorder that can involve all cartilage and proteoglycan-rich tissues. Clinical symptoms of relapsing polychondritis are often associated with recurrent inflammatory manifestations and functional impairment of such tissues. The disease has an insidious onset, and the first symptoms and clinical manifestations vary, making it easy to misdiagnose and miss the diagnosis.
View Article and Find Full Text PDFRelapsing polychondritis following PD-1 blockade diagnosed via 18F-FDG PET/CT and improved by steroid administration: a case report and literature review.
Front Immunol
September 2025
Respiratory and Critical Care Department, The First Hospital of China Medical University, Shenyang, China.
Background: Up to 22% of cancer patients treated with immune checkpoint inhibitors (ICIs) can experience immune-related adverse events (irAEs) that mimic rheumatic disease, such as relapsing polychondritis (RP), which is a rare autoimmune disease that mainly manifests as inflammation of airway cartilage.
Methods: We report a case of RP induced by humanized recombinant anti-PD-1 monoclonal antibody therapy (tislelizumab). 18F-Fluorodeoxyglucose positron emission tomography/ computed tomography (18F-FDG PET/CT) contributed to the diagnosis of RP, and methylprednisolone was used to effectively control its progression.
VEXAS Syndrome: Genetics, Gender Differences, Clinical Insights, Diagnostic Pitfalls, and Emerging Therapies.
Int J Mol Sci
August 2025
Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy.
VEXAS syndrome (Vacuoles, E1-enzyme, X-linked, Autoinflammation, and Somatic) is a recently identified late-onset autoinflammatory disorder characterized by a unique interplay between hematological and inflammatory manifestations. It results from somatic mutations in the gene, located on the short arm of the X chromosome. Initially, females were considered mere carriers, with the syndrome primarily affecting males over 50.
View Article and Find Full Text PDFBridging silicone and metallic stents for tracheobronchial stenosis in relapsing polychondritis: A case report.
Medicine (Baltimore)
August 2025
Department of Respiratory and Critical Care Medicine, Yichang Central People's Hospital, The First Clinical Medical College of China Three Gorges University, Yichang, China.
Rationale: Relapsing polychondritis is a rare autoimmune disease that commonly leads to tracheobronchial stenosis, presenting significant treatment challenges.
Patient Concerns: This case report describes a 64-year-old male with relapsing polychondritis who developed severe tracheobronchial stenosis.
Diagnoses: Computed tomography scanning revealed stenosis of the trachea and bronchi, while bronchoscopy confirmed occlusion or stenosis.
A case of tracheobronchomegaly misdiagnosed as COPD: case report and literature review.
BMC Pulm Med
August 2025
Clinical Medical College of Qinghai University, Xining City, Qinghai Province, 810000, China.
Background: Tracheobronchomegaly, also known as Mounier-Kuhn syndrome (MKS), is a rare congenital condition characterized by significant dilation of the trachea and main bronchi along with an abnormal wall structure. Diagnosis can be confirmed through computed tomography, pulmonary function tests, and diagnostic bronchoscopy. Currently, there is no curative treatment for MKS; thus, symptomatic and supportive care remain the primary therapeutic approaches.
View Article and Find Full Text PDF